Overview

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Status:
Terminated
Trial end date:
2018-06-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly rash).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb